Estée Lauder Q3 Results Show Continued Turnaround Momentum, But Valuation and Leverage Risks Persist

What happened

Estée Lauder reported fiscal Q3 2026 results that extend strong year-to-date performance, with organic fragrance sales rising double-digits and three of four regions growing, including high single-digit growth in Mainland China where the company outperformed the market. This follows a deeply challenged FY2025, which saw a $0.8B operating loss and $1.1B net loss due to travel retail weakness and impairments, but Q1 FY2026 had already shown early stabilization with 4% sales growth and a return to positive operating income. The new Beauty Reimagined restructuring plan is driving cost savings and margin improvements, with Q3 continuing that trend. However, the company's balance sheet remains stretched—net debt/EBITDA of 33.8x and negative interest coverage—and the stock trades at an EV/EBITDA of ~214x, well above a conservative DCF value of $10.76 per share. While the operational turnaround is gaining traction, the risk/reward is still unattractive given the high leverage and premium valuation, warranting a wait-and-see approach.

Implication

Estée Lauder's Q3 results confirm the early turnaround momentum seen in Q1 FY2026, with strong fragrance growth and outperformance in China supporting the Beauty Reimagined strategy. However, the master report's cautious stance persists: leverage is extreme (net debt/EBITDA ~34x, interest coverage negative), and the stock trades at a massive premium to intrinsic value. Investors should monitor for 2-3 consecutive quarters of mid-single-digit revenue growth, sustained gross margins above 73%, and clear progress in reducing net debt/EBITDA toward mid-single digits before considering a position. For now, the risk/reward is still unfavorable, and waiting for a better entry point or clearer evidence of sustainable free cash flow normalization is prudent.

Thesis delta

The Q3 results reinforce the early signs of stabilization seen in Q1 FY2026, with double-digit fragrance growth and China outperformance suggesting the restructuring is taking hold. However, this does not fundamentally alter the thesis: the company remains highly leveraged, valuation is extreme, and the recovery is far from proven. The path to a potential upgrade requires sustained margin expansion and visible de-leveraging, which are still at an early stage. The watch remains 'WAIT', as the turnaround is progressing but the margin of safety is insufficient for new capital.